公开(公告)号：US20150079077A1

公开(公告)日：2015-03-19

申请号：US14373930

申请日：2013-01-25

Applicant: Variation Biotechnologies, Inc.

Inventor： Marc J. Kirchmeier ,  David E. Anderson

IPC: A61K47/14 ,  C12N7/00 ,  A61K39/295 ,  C07K16/32 ,  A61K47/28 ,  A61K47/24

Abstract: The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present disclosure also provides methods for preparing compositions, including the aforementioned compositions (e.g., melt methods and spray injection methods among others).

Abstract translation: 本公开尤其提供了包含治疗剂（例如活减毒病毒抗原，治疗性蛋白质等）和脂质组分的组合物。 脂质组分可以包含或由本文所述的不同类型的脂质或脂质组成。 在一些实施方案中，治疗剂是不耐热的。 本公开还提供了制备组合物的方法，包括前述组合物（例如，熔融方法和喷射方法等）。

公开(公告)号：US20150044668A1

公开(公告)日：2015-02-12

申请号：US14387870

申请日：2013-03-27

Applicant: VARIATION BIOTECHNOLOGIES, INC.

Inventor： David E. Anderson ,  Jasminka Bozic ,  Barthelemy Ontsouka

IPC: C12Q1/70

CPC classification number: C12Q1/70 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2710/16134 ,  G01N33/5044 ,  G01N33/6854 ,  G01N2333/045 ,  G01N2469/20

Abstract: The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.

Abstract translation: 本公开提供了用于确定宿主细胞中HCMV感染水平的方法，并且延伸地确定样品中存在的中和抗体的水平。 本公开包括认识到具有荧光部分的HCMV病毒允许检测病毒感染（例如通过在与宿主细胞接触病毒之后评估细胞中的荧光）。 在一些实施方案中，HCMV感染的水平通过荧光检测来确定，其中病毒已经与来自受试者的测试样品（例如，血清样品）预孵育。 在一些实施方案中，受试者已经施用候选HCMV疫苗。

公开(公告)号：US20140308308A1

公开(公告)日：2014-10-16

申请号：US14357423

申请日：2012-11-09

Applicant: Variation Biotechnologies, Inc.

Inventor： David E. Anderson ,  Anne-Catherine Fluckiger

IPC: C07K14/005 ,  A61K39/245

CPC classification number: C07K14/005 ,  A61K39/245 ,  A61K2039/5258 ,  A61K2039/70 ,  C07K2319/00 ,  C07K2319/03 ,  C12N2710/16134 ,  C12N2740/13023 ,  C12N2760/20234

Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).

Abstract translation: 本公开提供了可用于治疗HCMV感染的组合物和方法。 如本文所述，组合物和方法基于免疫原性组合物的开发，其包括包含一种或多种莫洛尼鼠白血病病毒（MMLV）核心蛋白的病毒样颗粒（VLP），并且包括一种或多种HCMV表位，例如 例如，来自HCMV包膜糖蛋白gB和/或gH和/或凝胶蛋白pp65。 除此之外，本发明包括认识到抗原（例如，包膜糖蛋白和结构蛋白）的组合可以导致有益的免疫应答，例如包括体液应答（例如产生中和抗体）和细胞 反应（例如T细胞活化）。